Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals

Journal of Hepatology

Volumn 66, Issue 6, 2017, Pages 1173-1181

  Prenner, Stacey B ^a   VanWagner, Lisa B ^a   Flamm, Steven L ^a   Salem, Riad ^a   Lewandowski, Robert J ^a   Kulik, Laura ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cirrhosis; Hepatitis C virus; Hepatocellular carcinoma; Liver cancer; Liver transplant; Sustained viral response; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER PATIENT; CANCER SURGERY; CHEMOEMBOLIZATION; CHRONIC HEPATITIS C; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; ODDS RATIO; PRIORITY JOURNAL; RADIOEMBOLIZATION; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; AGED; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER TUMOR; TREATMENT FAILURE; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE;

EID: 85018428072     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.01.020     Document Type: Article

References (16)

1. Khullar, V., Firpi, R.J., Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol 7 (2015), 1843–1855.
2. Backus, L.I., Boothroyd, D.B., Phillips, B.R., Belperio, P., Halloran, J., Mole, L.A., A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 9 (2011), 509–516, e501.
3. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L. Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002), 975–982.
4. Bailly, F., Pradat, P., Virlogeux, V., Zoulim, F., Antiviral therapy in patients with hepatitis C virus-induced cirrhosis. Dig Dis 33 (2015), 613–623.
5. Majumdar, A., Kitson, M.T., Roberts, S.K., Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 43 (2016), 1276–1292.
6. El-Serag, H.B., Kanwal, F., Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. Hepatology 60 (2014), 1767–1775.
7. Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
8. Poordad, F., Hezode, C., Trinh, R., Kowdley, K.V., Zeuzem, S., Agarwal, K., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370 (2014), 1973–1982.
9. Lawitz, E., Matusow, G., DeJesus, E., Yoshida, E.M., Felizarta, F., Ghalib, R., et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 64 (2016), 360–369.
10. Sulkowski, M., Hezode, C., Gerstoft, J., Vierling, J.M., Mallolas, J., Pol, S., et al. Efficacy and safety of 8 weeks vs. 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2015), 1087–1097.
11. Poordad, F., Schiff, E.R., Vierling, J.M., Landis, C., Fontana, R.J., Yang, R., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63 (2016), 1493–1505.
12. Curry, M.P., Forns, X., Chung, R.T., Terrault, N.A., Brown, R. Jr., Fenkel, J.M., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107, e101.
13. Sulkowski, M.S., Naggie, S., Lalezari, J., Fessel, W.J., Mounzer, K., Shuhart, M., et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 312 (2014), 353–361.
14. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
15. Faria, L.C., Gigou, M., Roque-Afonso, A.M., Sebagh, M., Roche, B., Fallot, G., Ferrari, T.C., et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134 (2008), 1890–1899 [Quiz 2155].
16. Riaz, A., Awais, R., Salem, R., Side effects of yttrium-90 radioembolization. Front Oncol, 4, 2014, 198.